PharmaClik Login 
McKesson Canada
Advancing Health Outcomes for All ™
Touching Virtually Every Aspect of Health
As a diversified healthcare leader, our solutions help patients access life-changing therapies, whether because we deliver a third of all medications in Canada, consult with patients at our pharmacies, or partner with members and stakeholders of the healthcare industry. We do all this and much more as we pursue our purpose to advance health outcomes for all.
Advancing Health Outcomes for All ™
Touching Virtually Every Aspect of Health
As a diversified healthcare leader, our solutions help patients access life-changing therapies, whether because we deliver a third of all medications in Canada, consult with patients at our pharmacies, or partner with members and stakeholders of the healthcare industry. We do all this and much more as we pursue our purpose to advance health outcomes for all.
Distribution
Specialty Health
Retail Pharmacy Solutions
Automation Technology Solutions
Stories & Insights
McKesson Canada Launches Full-Suite Digital Offering for Patients and Healthcare Professionals
Industry-leading partnership with Auxita simplifies the specialty patient journey
MISSISSAUGA, ON, June 16, 2021 /CNW/ - Today, McKesson Canada is pleased to announce Canada's most robust set of integrated digital solutions intended to enhance specialty physicians' ability to support their patients through their entire healthcare journey. This initiative builds on our ongoing efforts to provide better digital offerings for Canadians.
"Managing a patient who requires a specialty medication entails detailed planning and an investment in time and resources to adequately diagnose and provide treatment," said Ramy Ayad, Senior Vice-President, Specialty Health, McKesson Canada. "Our goal with today's announcement is to alleviate the administrative burden on healthcare professionals in areas such as medication access, workflow and communication, so that more time can be spent on what matters most – caring for patients."
A strategic partnership delivering market-leading digital capabilities
McKesson Canada, in partnership with leading Canadian technology firm Auxita, is expanding modern digital capabilities to simplify the patient journey. These solutions and capabilities will enable digital connectivity into Patient Support Programs (PSPs), streamlining the clinical workflow and patient experience to navigate complexities related to specialty medications and providing real time data on where the patient is on their treatment journey.
The technology facilitates patient to physician communication and eliminates administrative tasks, creating significant program efficiencies, enhancing the patient experience and shortening the amount of time to receive therapy. The platform will be Electronic Medical Record (EMR) agnostic and will be available for providers who do not have compatible EMRs.
"The Auxita platform is a comprehensive digital health care ecosystem. It delivers actionable insights, evidence-based pathways, simplified enrolment, and seamless communication to improve patient care," said Matt Cahill, CEO at Auxita. "We are looking forward to this partnership positively impacting the lives of Canadians, as we simplify the specialty healthcare experience."
A new, simplified specialty patient journey
Unlike existing solutions on the market today, the Auxita platform integrates directly into the existing office workflow. It seamlessly connects with EMRs to provide real time data on where the patient is on their treatment journey.
"As the largest technological initiative in the history of McKesson Canada Specialty Health, the new platform offers intelligent condition-specific alerts and reminders, getting patients started on a treatment plan sooner where a prescription is already available, and creates patient programs that support better treatment outcomes," continued Ayad.
McKesson Canada expects all digital capabilities to be fully operational by December 2021. For more information about this initiative, please contact media@mckesson.ca.
About McKesson Canada
Founded more than 100 years ago, McKesson Canada is dedicated to delivering vital medicines, supplies and information technologies that enable the healthcare industry to provide patients better, safer care. Our solutions empower pharmacies, our biopharma partners, hospitals and other healthcare institutions by enabling them to get closer to the millions of patients they serve every single day, while contributing to the quality and safety of care in Canada. For more information, please visit mckesson.ca.
About Auxita
Auxita is a secure digital platform that seamlessly integrates with Electronic Medical Records to link patient data and clinical information across multiple systems. It connects doctors, patients, and patient support programs while eliminating the administrative tasks that can overwhelm today's healthcare providers. Auxita has an established footprint in Canada's healthcare sector and collaborates with strategic partners to ensure a consistent and secure flow of information throughout the patient journey. For more information on Auxita's next-generation medical technology that leads to better care, visit www.auxita.com.
SOURCE MCKESSON CANADA
For further information: Andrew Forgione, Media Relations and Public Affairs, Andrew.Forgione@mckesson.ca, 905.671.4586
- Publication Date
- 21-06-16
McKesson Canada Opens New State-of-the Art Distribution Centre in Surrey British Columbia
Supporting British Columbia’s Future Health
Surrey, BC (June 8, 2023) – To support British Columbia’s rising healthcare needs, McKesson Canada opens a new state-of-the-art, 233,000 square-foot facility in Surrey, British Columbia (BC). The new distribution centre (DC) delivers pharmaceutical medications, vaccines, specialty pharmaceuticals, and over-the-counter products to over 1,300 hospitals, clinics, and pharmacies across BC. McKesson Specialty Pharmacy on site manages complex specialty medications, providing quality care for patients across the province.
- New 233,000 square-foot facility ensures expanded capacity to support provincial medication delivery needs long-term and strengthens medication delivery infrastructure
- McKesson Canada’s new distribution centre features industry-leading automation to accelerate fulfillment and increase efficiency and productivity
- Integration of on-site Specialty Pharmacy campus ensures support in rise of complex therapies
As part of McKesson Canada’s distribution modernization plan, $175 million dollars was invested in the development and design of the Surrey DC to integrate industry-leading automation technology and strengthen efficiency and productivity. The DC uses best-in-class technology and processes to increase accuracy, protect against volume fluctuations and doubles potential capacity to over 235,000 units shipped daily. This investment ensures McKesson Canada can meet Canada’s rising need for complex specialized medications and respond to BC’s future healthcare demands, particularly the expected 63 per cent[i] rise in seniors over the next 20 years, who typically have more complex conditions.
“Today, we are showcasing our unwavering dedication to improve health outcomes of Canadians. From strategic concept to operations, McKesson Canada’s Surrey distribution centre is a showcase of innovation that blends the state-of-the-art technology and optimized processes that secure our capacity to support the growing healthcare needs of British Columbians for the long term,” said Joan Eliasek, President, McKesson Canada. “We take great pride in our investment in British Columbia and in our responsibility to deliver lifesaving medications reliably and safely across the province for many years to come.”
State-of-the-Art Technology, Processes and Automation
State-of-the-art automation technology enables more efficient and accurate product picking. The new DC utilizes a system that picks products from over 22,000 storage containers, delivering them directly to the operators who ensure quality and accuracy. The automation process allows for vast quantities of product to flow through the distribution system, with real-time monitoring and forecasting of required product volume levels. Picked products are released and sequenced according to delivery route, all through automation to ensure the right product gets to the right destination for precise just-in-time delivery.
Significant investment has also been made in cold chain storage to support Canada’s rising need for more complex medications that require fridge and freezer storage, such as COVID-19 vaccinations.
The Surrey DC is the last of McKesson Canada’s transformation and modernization initiatives in Western Canada, including building new Edmonton and Winnipeg DCs. Reaching this milestone means that McKesson Canada is prepared to support and react quickly in times of environmental crisis or emergencies like wildfires or flooding. Each McKesson Canada DC in Western Canada has contingency planning to be able to support provinces in the event of a disruption or crisis.
Bedrock of Community and Independent Pharmacy
Just-in-time delivery is a hallmark of the McKesson Canada distribution system, creating an infrastructure that allows for continual flow of goods into the community and reliable access to medication. McKesson Canada’s distribution system has been a key enabler for independent pharmacy. The modernization of the Surrey DC processes, tools and equipment support operational excellence and enhances our customer offering.
“The complexity of just-in-time delivery within an ecosystem that delivers much needed medication to every community in Canada, the next day, every day is extraordinary,” says Jean-Philippe Blouin, Senior Vice-President Pharmaceutical Distribution & Operations, McKesson Canada. “The value and enhanced features of our new Surrey distribution centre ensures that we provide reliable service and further demonstrates our commitment to our patients and our customers in BC.”
The Rise of Specialized Medication Needs
The use of specialty medications and therapeutic treatments for both acute and chronic care patients continues to rise in Canada. In 2021, specialty drugs had a 9.5 per cent growth rate compared to traditional drugs at 2.9 per cent.[ii] The innovative McKesson Specialty Pharmacy provides care to patients from a wide range of therapeutic specialties such as neurology, oncology, immunology and ophthalmology. Molecules are compounded on site in state-of-the-art cleanrooms where hazardous and non-hazardous medications are handled in sterile environments. The integration of the McKesson Specialty Pharmacy in the Surrey DC allows for more efficient access and delivery to patient’s homes, hospitals, and infusion clinics.
Environmental Focus
Situated on 14 acres of land, the new DC office space was designed with consideration for environmental sustainability. The new DC features LED low energy lighting, low flow water fixtures, underground rainwater collection, native landscaping to support local birds and insects and electric vehicle charging stations.
The Surrey DC employs 180 people and supports additional jobs in partner businesses including transportation.
About McKesson Canada
McKesson Canada is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of healthcare at www.McKesson.ca
For more information: media@mckesson.ca
[i] Ip, Frank and Lavoie, Sebastien. ”PEOPLE 2020: BC Sub-Provincial Population Projections.” Government of British Columbia, BC Stats.,https://www2.gov.bc.ca/assets/gov/data/statistics/people-population-community/population/people_population_projections_highlights.pdf
[ii]“2022 Drug Data Trends & National Benchmarks.” TELUS Health. Pg. 12, https://plus.telushealth.co/blogs/health-benefits/wp-content/uploads/TELUS-Health-Drug-Data-Trends-Report-2022.pdf
- Publish Date
- 6/8/23
Roche Canada and McKesson Canada Inaugural Innovation Challenge Enhances the Patient Experience
MISSISSAUGA, ON - January 11, 2024 - Hoffmann-La Roche Limited (Roche Canada) is proud to announce a dynamic collaboration with McKesson Canada (McKesson) which has resulted in solutions that will optimize the patient journey and potentially shorten overall time to therapy.
The two industry leaders brought collaborative teams together for an intensive six-week innovation challenge aimed at removing barriers, enhancing the patient experience, streamlining administrative processes, and expediting reimbursement within existing patient support programs. This collaboration demanded a creative approach to strategically design solutions within the constraints of available resources.
When a patient is diagnosed with a chronic condition or disease like Multiple Sclerosis (MS) or cancer, it can be challenging to navigate the complex healthcare systems. Patient Support Programs (PSPs) work to simplify the process and ease the patient’s experience.
“Roche created this innovation challenge to explore what could be possible in the patient support program space and to see what - with an open-minded partner like McKesson Canada - we could do differently, better, faster for patients,” said Roger Tam, Vice President, Legal, Compliance, and Innovation at Roche Canada. “Design thinking empowered Roche Canada and McKesson Canada employees to frame opportunities and create solutions that will deliver significant value to all stakeholders, especially patients.”
The innovation challenge culminated in a pitch competition, where teams presented their proposals to a seasoned panel of leaders from both Roche Canada and McKesson Canada. The pitches underwent rigorous evaluation, resulting in the prioritization of the highest-scoring proposal for implementation over the next six to 12 months. Ultimately, the panel found all solutions to be compelling enough for implementation; it was simply a matter of determining the optimal timeline for each.
The two winning innovations addressed the cumbersome administrative challenges experienced by both patients and healthcare providers during PSP enrolment. Through streamlined processes, these solutions not only minimize time and redundancy for all stakeholders but also significantly accelerate access to vital therapies.
“When you have a patient with a complex disease, you do everything you can to get them to critical treatment as fast as you can,” said Rebecca Yu, Vice President/General Manager, Biopharma Operations & Customer Experience, McKesson Canada. “The Roche McKesson Innovation Challenge shows what is possible when you change your approach, share a common goal and come together with committed partners. We are tremendously proud of our teams and inspired by the value they have created with new solutions that will positively impact care and experience for patients!”
McKesson Canada is a Patient Support Program partner to Roche Canada and works to simplify a patient’s health journey by helping them to navigate the various healthcare systems, including supporting the administration process to ensure timely access to treatment.
The success of this innovation challenge not only underscores Roche Canada and McKesson Canada’s ability to swiftly implement ideas but also marks a pivotal step towards fostering a proactive culture of idea sharing, collaboration and innovation. Roche Canada and McKesson remain committed to revolutionizing PSPs and setting a new standard for excellence in patient care and experience.
About Roche Canada
Patients and science are at the heart of everything we do. At Roche, our passion for science and our commitment to relentlessly pursuing the impossible for patients has made us one of the world’s leading pharmaceutical, in vitro diagnostics, and healthcare technology companies. And we’re adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries.
We're an innovator across major disease areas, including oncology, infectious diseases, diabetes, ophthalmology, and diseases of the central nervous system.
Roche Canada was founded in 1931 and employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics and Diabetes Care divisions in Laval, Quebec. For more information, please visit www.RocheCanada.com, or follow Roche Canada on LinkedIn, or on Twitter @RocheCanada.
About McKesson Canada
McKesson Canada is a diversified health-care services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of health care at www.McKesson.ca
For information, contact:
Jennifer Mota
Roche Canada
Jennifer.mota@roche.com
Michelle Lee-Gracey
McKesson Canada
media@mckesson.ca
